TerminatedNot Applicable

Feasibility and Accuracy of Hybrid Magnetic Resonance and Positron Emission Tomography With 18F-Fluorodeoxyglucose in Diagnosing Cardiac Sarcoidosis

Stopped: Lack of funding and support

United States5 participantsStarted 2019-05-21

Plain-language summary

The purpose and objectives of the study is to establish the feasibility of the simultaneous PET/MR in patients with cardiac sarcoidosis, determine relationships between various imaging biomarkers like extracellular volume (ECV) and standardized uptake values (SUV) from FDG-PET and to evaluate the diagnostic accuracy of the simultaneous method in comparison to the PET/CT and cardiac MRI.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓.Subjects older than 18 years of age with high suspicion of cardiac sarcoidosis and/or biopsy proven extracardiac sarcoidosis and/or positive HRS criteria will be enrolled.

Exclusion criteria

✕. Coronary artery disease
✕. Insulin dependent diabetes
✕. Claustrophobia
✕. Pregnancy/nursing
✕. Presence of pacemaker or automatic implantable cardioverter-defibrillator
✕. Impaired renal function (estimated glomerular filtration rate \<45 ml/min/1.73 m2) will be excluded.
✕. Inability to undergo PET/MRI due to any other condition.

What they're measuring

diagnosing cardiac sarcoidosis using combined 18F-FDG-PET/MRI examination

Timeframe: baseline through 24 hours

Trial details

NCT IDNCT03923049

SponsorUniversity of Alabama at Birmingham

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-02

View on ClinicalTrials.gov More Cardiac Sarcoidosis trials